Cargando…
Models and methods: a perspective of the impact of six IMI translational data-centric initiatives for Alzheimer’s disease and other neuropsychiatric disorders
The Innovative Medicines Initiative (IMI), was a European public–private partnership (PPP) undertaking intended to improve the drug development process, facilitate biomarker development, accelerate clinical trial timelines, improve success rates, and generally increase the competitiveness of Europea...
Autores principales: | North, Hilary, Hofmann-Apitius, Martin, Kas, Martien J. H., Marston, Hugh, Haas, Magali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374208/ https://www.ncbi.nlm.nih.gov/pubmed/37521302 http://dx.doi.org/10.3389/fneur.2023.1174079 |
Ejemplares similares
-
Avoiding fragmentation: The potential of synergistic efforts across the IMI portfolio
por: Díaz, Carlos, et al.
Publicado: (2022) -
Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden
por: Iravani, Behnam, et al.
Publicado: (2022) -
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021) -
7,8-Dihydroxyflavone and Neuropsychiatric Disorders: A Translational Perspective from the Mechanism to Drug Development
por: Yang, Shaojie, et al.
Publicado: (2022) -
Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies
por: Jaramillo-Jimenez, Alberto, et al.
Publicado: (2021)